Tolcapone
- 1 May 1998
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 50 (5_suppl_5) , S1-S2
- https://doi.org/10.1212/wnl.50.5_suppl_5.s1
Abstract
A new class of drugs, catechol O-methyltrasferase (COMT) inhibitors, has shown promise for treating PD in Phase III clinical studies. In patients receiving levodopa, most (about 70%) of the orally administered levodopa is metabolized rapidly by peripheral dopa decarboxylase to dopamine, which is further metabolized by intracellular monoamine …Keywords
This publication has 4 references indexed in Scilit:
- Changes in policy for publishing manuscripts in NeurologyNeurology, 1997
- X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapyJournal of Neurology, Neurosurgery & Psychiatry, 1997
- The Dopamine D2 Receptor Gene (DRD2) and Neuropsychiatric DisordersCNS Drugs, 1994
- OCCURRENCE AND DISTRIBUTION OF NEURONS WITH MULTIPLE SYNAPTIC MESSENGERS AND SOME FUNCTIONAL ASPECTSClinical Neuropharmacology, 1984